{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-038623","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2021-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.830707+00:00","generated_at":"2026-06-30T01:40:15.728451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Viking reports Q2 net loss of $15.4M, cash $228.3M; VK2809 VOYAGE enrollment continues","bullets":["Q2 net loss $15.4M ($0.20/sh) vs $9.6M ($0.13/sh) in Q2 2020; R&D expenses rose to $12.8M from $7.8M.","Cash, equivalents and short-term investments $228.3M at June 30, down from $248.4M at Dec 31, 2020.","Phase 2b VOYAGE study of VK2809 for NASH enrolling; top-line data expected in 2022.","VK0214 Phase 1 met primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.","Six-month net loss $29.4M ($0.38/sh) vs $19.3M ($0.27/sh) in H1 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-038623","json":"https://secwatch.observer/filing/0001564590-21-038623.json","markdown":"https://secwatch.observer/filing/0001564590-21-038623.md","text":"https://secwatch.observer/filing/0001564590-21-038623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/0001564590-21-038623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/vktx-8k_20210728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:40:15.728451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}